2022
Association of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study
Miano TA, Hennessy S, Yang W, Dunn TG, Weisman AR, Oniyide O, Agyekum RS, Turner AP, Ittner CAG, Anderson BJ, Wilson FP, Townsend R, Reilly JP, Giannini HM, Cosgriff CV, Jones TK, Meyer NJ, Shashaty MGS. Association of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intensive Care Medicine 2022, 48: 1144-1155. PMID: 35833959, PMCID: PMC9463324, DOI: 10.1007/s00134-022-06811-0.Peer-Reviewed Original ResearchConceptsPiperacillin-tazobactamKidney biomarkersCystatin CAcute kidney injury riskProspective cohort studyCystatin C concentrationCystatin C measurementKidney function biomarkersCreatinine secretionAntibiotic initiationCohort studyProspective cohortIll adultsClinical outcomesAssociation of vancomycinAntibiotic treatmentTubular secretionCreatinine concentrationTreatment weightingResultsThe studyTrue injuryHigh incidenceCreatinineDay 14Early changes
2011
Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD)
Wilson FP, Berns JS. Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD). Clinical Nephrology 2011, 77: 329-331. PMID: 22445477, PMCID: PMC3359699, DOI: 10.5414/cn106993.Peer-Reviewed Original ResearchConceptsContinuous renal replacement therapyContinuous venovenous hemodialysisAcute kidney injuryRenal replacement therapyPopulation of patientsDialysis flow rateKidney injuryVancomycin levelsIntensive careReplacement therapyIntermittent dialysisSubtherapeutic levelsLow bloodNephrology traineesAntibioticsHemodialysisPatientsInjuryTherapyPopulationVancomycinBloodDialysisCare